• Multimodal imaging in the characterization of tumors to assess tumor aggressiveness, diagnostic work-up and treatment response evaluation in prostate cancer, cervical cancer, breast cancer, sarcomas, spinal metastases, neuroendocrine tumors, GISTs, colorectal cancers, liver malignancies, multiple myeloma and lymphoma
  • Characterization of vascular inflammation inclusive vulnerability in atherosclerosis, treatment selection and treatment response evaluation using PET, MRI and US
  • Detection and treatment response evaluation in inflammatory and fibrosing diseases using different imaging modalities and PET tracers
  • Characterize pituritary microadenomas, remnant adenomas following surgery and hypophysitis by the use of different MRI and PET techniques
  • Radionuclide therapies for treatment of non-Hodgkin lymphoma, neuroendocrine tumors (NET) and Selective Internal Radiation Therapy (SIRT) 
  • Development and testing of novel radionuclide therapies with emphasis on alpha-emitters
  • Molecular imaging and quantification of neurological diseases
  • Ultrasound-guided percutaneous ethanol injection treatment in patients with metastatic lymph nodes from thyroid carcinoma
  • Development of new biomarkers using radiomics and artificial intelligence (AI) for the characterization of diseases
Page visits: 3136